Login to Your Account



Clinic Roundup


Thursday, September 22, 2011
Repros Therapeutics Inc., of The Woodlands, Texas, said it started dosing of the final cohort in its Phase II low-dose trial of Proellex, which will involve a dose of 12 mg per day.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription